(NP (NP Molecular/JJ basis/NN) (PP of/IN (NP (NP a/DT multiple/JJ lymphokine/NN deficiency/NN) (PP in/IN (NP (NP a/DT patient/NN) (PP with/IN (NP severe/JJ combined/JJ immunodeficiency/NN)))))) ./.)
(S (NP-SBJ We/PRP) (VP have/VBP (ADVP-TMP previously/RB) (VP reported/VBN (SBAR that/IN (S (NP-SBJ (NP the/DT T/NN lymphocytes/NNS) (PP of/IN (NP (NP a/DT child/NN) (PP with/IN (NP severe/JJ combined/JJ immunodeficiency/NN))))) (VP are/VBP (ADJP-PRD defective/JJ) (PP in/IN (NP (NP the/DT transcription/NN) (PP of/IN (NP (NP several/JJ lymphokine/NN genes/NNS) (SBAR (WHNP-27 that/WDT) (S (NP-SBJ *T*-27/-NONE-) (VP include/VBP (NP (NP-COOD (NP IL2/NN) ,/, (NP IL3/NN) ,/, (NP IL4/NN) ,/, and/CC (NP IL5/NN)) ,/, (SBAR (WHNP-28 which/WDT) (S (NP-SBJ *T*-28/-NONE-) (VP encode/VBP (NP (NP interleukins/NNS (NP-COOD (NP 2/CD) ,/, (NP 3/CD) ,/, (NP 4/CD) ,/, and/CC (NP 5/CD))) (PRN -LRB-/-LRB- (NP-COOD (NP IL-2/NN) ,/, (NP -3/CD) ,/, (NP -4/CD) ,/, and/CC (NP -5/CD)) -RRB-/-RRB-)))))))))))))))))) ./.)
(S (S (NP-SBJ *-29/-NONE-) (VP To/TO (VP determine/VB (SBAR whether/IN (S (NP-SBJ (NP the/DT defect/NN) (PP in/IN (NP (NP the/DT patient/NN 's/POS) T/NN lymphocytes/NNS))) (VP involved/VBD (NP (NP a/DT trans-acting/JJ factor/NN) (ADJP common/JJ (PP to/TO (NP the/DT affected/VBN lymphokine/NN genes/NNS)))))))))) ,/, (NP-SBJ-29 we/PRP) (VP examined/VBD (NP (NP the/DT ability/NN (S *ICH*-30/-NONE-)) (PP of/IN (NP (NP nuclear/JJ factors/NNS) (PP from/IN (NP (NP the/DT patient/NN 's/POS) T/NN lymphocytes/NNS)))) (S-30 (NP-SBJ */-NONE-) (VP to/TO (VP bind/VB (NP (NP response/NN elements/NNS) (ADJP present/JJ (PP in/IN (NP (NP the/DT regulatory/JJ region/NN) (PP of/IN (NP IL2/NN))))))))))) ./.)
(S (NP-SBJ-COOD (NP Nuclear/JJ factor/NN NF-kB/NN) ,/, (NP (NP activation/NN protein/NN 1/CD) (PRN -LRB-/-LRB- (NP AP-1/NN) -RRB-/-RRB-)) ,/, (NP OCT-1/NN) ,/, and/CC (NP NF-IL-2B/NN binding/NN activity/NN)) (VP were/VBD (ADJP-PRD normal/JJ)) ./.)
(S (PP In/IN (NP contrast/NN)) ,/, (NP-SBJ (NP the/DT binding/NN) (PP of/IN (NP (NP (NP the/DT nuclear/JJ factor/NN) (PP of/IN (NP activated/VBN T/NN cells/NNS))) (PRN -LRB-/-LRB- (NP NF-AT/NN) -RRB-/-RRB-))) (PP-COOD (PP to/TO (NP (NP its/PRP$ response/NN element/NN) (PP in/IN (NP the/DT IL2/NN enhancer/NN)))) and/CC (PP to/TO (NP (NP an/DT NF-AT-like/JJ response/NN element/NN) (ADJP present/JJ (PP in/IN (NP the/DT IL4/NN enhancer/NN))))))) (VP was/VBD (ADJP-PRD abnormal/JJ)) ./.)
(S (S (NP-SBJ *-31/-NONE-) (VP To/TO (VP ascertain/VB (SBAR whether/IN (S (NP-SBJ the/DT abnormal/JJ NF-AT/NN binding/NN activity/NN) (VP was/VBD (ADJP-PRD related/JJ (PP to/TO (NP an/DT impaired/JJ function/NN))))))))) ,/, (NP-SBJ-31 we/PRP) (VP transfected/VBD (NP (NP-COOD (NP patient/NN) and/CC (NP control/NN)) T/NN lymphocytes/NNS) (PP with/IN (NP (NP constructs/NNS) (VP containing/VBG (NP (NP the/DT reporter/NN gene/NN) (VP encoding/JJ (NP (NP (NP chloramphenicol/NN acetyl/NN transferase/NN) (PRN -LRB-/-LRB- (NP CAT/NN) -RRB-/-RRB-)) (PP under/IN (NP (NP the/DT control/NN) (PP-COOD (PP of/IN (NP the/DT entire/JJ IL2/NN regulatory/JJ region/NN)) or/CC (PP of/IN (NP (NP multimers/NNS) (PP of/IN (NP individual/JJ enhancer/NN sequences/NNS)))))))))))))) ./.)
(S (NP-SBJ (NP CAT/NN expression/NN) (VP directed/VBN (NP */-NONE-) (PP-COOD (PP by/IN (NP-LGS the/DT IL2/NN regulatory/JJ region/NN)) or/CC (PP by/IN (NP-LGS (NP a/DT multimer/NN) (PP of/IN (NP the/DT NF-AT-binding/JJ site/NN))))))) (VP was/VBD (ADJP-PRD markedly/RB lower/JJR) (PP in/IN (NP the/DT patient/NN)) (PP relative/JJ to/TO (NP controls/NNS))) ./.)
(S (PP In/IN (NP contrast/NN)) ,/, (NP-SBJ (NP CAT/NN gene/NN expression/NN) (VP directed/VBN (NP */-NONE-) (PP by/IN (NP-LGS (NP a/DT multimer/NN) (PP of/IN (NP the/DT (ADJP OCT-1/NN proximal/NN -LRB-/-LRB- OCT-1p/NN -RRB-/-RRB- -binding/JJ) site/NN)))))) (VP was/VBD (ADJP-PRD equivalent/JJ) (PP in/IN (NP-COOD (NP patient/NN) and/CC (NP controls/NNS)))) ./.)
(S (NP-SBJ These/DT results/NNS) (VP indicate/VBP (SBAR that/IN (S (NP-SBJ (NP an/DT abnormality/NN) (UCP (UCP-COOD (PP of/IN (NP *RNR*-32/-NONE-)) \//CC (VP or/CC (NP *RNR*-32/-NONE-))) (NP-32 influencing/JJ))) (VP NF-AT/NN (VP may/MD (NP (NP underlie/VB the/DT multiple/JJ lymphokine/NN) (PP deficiency/NN (NP in/IN this/DT)))))))) patient/NN)
